Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIMILAR trial of switching from Remicade to Inflectra in inflammatory bowel disease remission
NL-OMON43635Phase 4Active, not recruiting
- Sponsor
- Santeon
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of infliximab in autoimmune colitis and Crohn's disease (2 arms), sponsored by Santeon. Primary endpoints: Duration of clinical remission and Relapse rate. Started Jan 2016; status: active, not recruiting.
02
Drugs
infliximab
03
Conditions
autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on NL-OMON43635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43635.